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Abstract
Background: There has been a marked increase in the incidence of, and concern regarding,
human Campylobacter jejuni and C. coli infections worldwide during the last decade. As the highest
infectious disease control apparatus in Taiwan, we aimed to describe the character of
Campylobacter isolates from infected children, as well as basic information about the patients, from
December 2003 to February 2005.
Methods: A total of 894 fecal specimens were collected by several clinics and hospitals from
children who had diarrhea, followed by plating onto selective media. Drug susceptibility test of the
isolates from these specimens were conducted by disc diffusion method and their serotypes were
also studied using commercial antisera made in Japan.
Results: The isolation rate of Campylobacter during these 15 months was 6.8% and was higher in
winter (11.1%) than in other seasons. C. jejuni was the most prevalent (95.1%) species in northern
Taiwan, comparable to other developed countries. Among the 61 Campylobacter isolates, most
were resistant to tetracycline (93.4%), nalidixic acid (91.8%), ciprofloxacin (90.2%), and ampicillin
(85.5%). Erythromycin-resistant isolates represented 3.3% of all isolates, suggesting that this drug
may be the first choice for treatment. The serotypes of the 61 isolates were demonstrated and only
41.4% were typable.
Conclusion: In this study, the Taiwan CDC provided an epidemiological analysis of Campylobacter
infection, including the isolation rate, age, seasonal distribution, antimicrobial drug susceptibility
patterns, and serotypes of the isolates from pediatric patients in northern Taiwan from 2003 to
2005.
Background
Infection with thermophilic Campylobacter species, espe-
cially C. jejuni and C. coli, is one of the most common
causes of bacterial diarrhea in humans worldwide [1-3].
The pathogen is also part of the normal intestinal flora of
domestic and wild animals [4,5]. Infections caused by this
pathogen are usually sporadic, occurring in the summer
months and early fall in many countries and usually fol-
lowing the ingestion of improperly handled foods.
Among developing countries in Asia, the incidence of dis-
eases caused by Campylobacter is much higher than that in
developed countries [4]. In Thailand, the overall isolation
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rate of Campylobacter from diarrheal children under year 5
was 13.0% [6]. This rate was also present about 12.1% in
Laos that C. jejuni together with C. coli occupied 7.1% and
4% of enteric infection in children aged < 1 year and 1–5
years, respectively [7]. In the United States, the incidence
of campylobacteriosis was 12.71 per 100,000 population
and has often exceeded those of salmonellosis and shigel-
losis during the past years [8,9]. Campylobacter spp. are
also the major pathogens, along with enterotoxigenic
Escherichia coli, responsible for traveler's diarrhea [4]. The
symptoms associated with campylobacteriosis range from
mild enteritis with or without bloody diarrhea, fever,
abdominal pain to severe invasive diseases, and are some-
times more severe than Salmonella and Shigella infections
[10]. In addition, Campylobacter  infection is associated
with the development of Guillain-Barre syndrome, which
is an autoimmune disorder of the peripheral nervous sys-
tem and characterized by acute flaccid paralysis [11].
Most Campylobacter infections are self-limited, and treat-
ment is usually supportive. Antimicrobial therapy should
still be considered if prolonged or severe symptoms
occurred. Macrolides (erythromycin) and fluoroquinolo-
nes (ciprofloxacin) are recommended as first and alterna-
tive choices of therapy, respectively [12,13]. However, a
rapid increasing proportion of Campylobacter strains have
developed resistance to the fluroquinolones and mac-
rolides in the past decade, especially in Southeast Asia, the
United States and Europe. This illustrated the antimicro-
bial resistance of Campylobacter has emerged worldwide
[14].
National surveillance programs that facilitate monitoring
of sporadic and outbreak cases of human campylobacteri-
osis in many developed countries, such as the United
States and members of the European union, are available
[4]. In contrast, the information of the incidence of
campylobacteriosis in developing countries is limited,
and most are from laboratory-based data. Therefore, the
rate of Campylobacter infection in those countries may be
underestimated [4,15,16]. In 1998, Lin et al. has reported
campylobacteriosis in diarrheal children in central Tai-
wan with 2.5% isolation rate and showed more prevalent
in winter [16]. As the highest health and infectious dis-
eases control apparatus in Taiwan, we described here the
character of Campylobacter isolates from infected children,
including the isolation rate, seasonal distribution, antimi-
crobial drug susceptibility patterns, and serotypes as well
as basic information about the patients, including age,
gender, and symptoms, in northern Taiwan from Decem-
ber 2003 to February 2005.
Methods
Collection and transportation of clinical specimens
The study population in the present study consists of chil-
dren under age 17 in northern Taiwan with loose, watery
or bloody diarrhea and divides into 5 age-groups as fol-
lows: (1) < 4 years old (infant stage), (2) 4–7 (kindergar-
ten stage), (3) 7–10 (elementary school stage 1), (4) 10–
13 (elementary school stage 2) and (5) > 13 (junior high
school stage and above). The fecal specimens were col-
lected from more than 30 clinics and hospitals in north-
ern Taiwan, including Taipei, Taoyuan, Hsin-Chu, Yilan,
and Keelung. All the samples which were transported in
Cary-Blair transport medium (BD Diagnostic Systems,
Sparks, MD) or buffered glycerol saline (Creative Micro-
biologicals, Ltd., Taipei, Taiwan) were previously tested
the presence of other enteric pathogens such as Shigella
spp., Salmonella spp. and Vibrio spp. Specimens free of the
above pathogens were chosen in our study. Therefore,
mixed infection with multiple pathogens in this study has
been excluded. A total of 894 clinical specimens from dif-
ferent patients gathered between December 2003 and
February 2005 were chosen.
Enrichment or plating medium selection
After arrival at our laboratory, the specimens were directly
inoculated onto two prepared selective media (usually
delay 1–7 days between stool collection and plating):
modified cefoperazone charcoal deoxycholate agar
(mCCDA, Creative Microbiologicals, Ltd., Taipei, Taiwan)
and charcoal-containing selective medium (CSM, BD
Diagnostic Systems, Sparks, MD), followed by incubation
at 42°C for 48 hours in a microaerobic atmosphere con-
taining 5% O2, 10% CO2, and 85% N2 generated by
CampyPak (BD Diagnostic Systems, Sparks, MD). If
enrichment was needed to recover low numbers of organ-
isms due to delayed transport to the laboratory, swabs or
stools were first inoculated into brain heart infusion broth
(BHI, Creative Microbiologicals, Ltd., Taipei, Taiwan) and
Campylobacter enrichment broth, each of which contained
cefoperazone (8 mg/L), amphotericin B (5 mg/L), teico-
planin, and 5% lysed horse blood, followed by incuba-
tion at 37°C for 48 hours. Finally, the broth suspensions
were inoculated onto mCCDA or CSM agar for another 48
hours.
Phenotypic characterization of isolates
For further confirmation of Campylobacter, suspected colo-
nies, which were morphologically smooth, gray, flat, and
moist, were sub-cultured from each plate onto fresh blood
agar plates. They were checked by Gram staining and sev-
eral biochemical reactions including oxidase production,
catalase production, and sodium hippurate hydrolysis.
Oxidase- and catalase-positive colonies exhibiting a char-
acteristic Gram stain appearance (e.g., Gram-negative,
curved rods) could be reported as Campylobacter  spp.BMC Infectious Diseases 2008, 8:151 http://www.biomedcentral.com/1471-2334/8/151
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Hydrolysis of sodium hippurate is the major identifica-
tion test used for C. jejuni. Campylobacter species giving a
positive hippurate hydrolysis result could be reported as
C. jejuni, with no other additional tests required. Isolates
giving a negative result for hippurate hydrolysis were fur-
ther identified by PCR in order to distinguish some iso-
lates of C. jejuni that express the hippuricase gene (hipO),
but are negative for the hippurate hydrolysis phenotype
from C. coli, another important species of Campylobacter
that lacks hippuricase activity, as described below.
Conventional PCR identification
To confirm isolates that were negative for hippurate
hydrolysis activity as C. jejuni or C. coli, conventional PCR
was conducted. DNA was extracted from bacterial suspen-
sions by boiling at 100°C for 15 min. Two primer pairs
[17,18] CJF (5'-ACTTCTTTATTGCTTGCTGC-3'), CJR (5'-
GCCACAACAAGTAAAGAAGC-3') and COL1 (5'-
ATGAAAAAATATTTAGTTTTTGCA-3'), COL2 (5'-ATTT-
TATTATTTGTAGCAGCG-3') each were used to amplify
the hipO gene from C. jejuni and the ceuE gene from C. coli,
respectively. PCR was performed using conditions
described, as previously reported [17,18].
Antimicrobial susceptibility test
To determine the susceptibility of Campylobacter isolates
to antimicrobial agents, they were suspended in Mueller-
Hinton broth (Creative Microbiologicals, Ltd., Taipei, Tai-
wan) to the concentration of McFarland No. 0.5 and bac-
terial cells were inoculated on Mueller-Hinton agar plates
(Creative Microbiologicals, Ltd., Taipei, Taiwan) contain-
ing 5% sheep blood after incubation for 48 hours in a
microaerobic atmosphere. Discs containing ampicillin
(10 μg), chloramphenicol (30 μg), nalidixic acid (30 μg),
ciprofloxacin (5 μg), cephalothin (30 mg), clindamycin
(2 μg), erythromycin (15 μg), gentamicin (10 μg), strepto-
mycin (10 μg), and tetracycline (30 μg) (Oxoid, Hamp-
shire, UK) were placed on the inoculated plates. The plates
were then incubated at 42°C for 48 hours in a microaero-
bic atmosphere. Interpretation of the susceptibility test,
including susceptible (S), intermediate (I) and resistant
(R), was carried out (Available from http://
www.sfm.asso.fr/nouv/general.php?pa=2) [19,20]. Sta-
phylococcus aureus ATCC 29213, Escherichia coli ATCC
25922, and Pseudomonas aeruginosa ATCC 27853 were
used as positive controls.
Serotyping of somatic antigen
For serotyping of C. jejuni, a commercial antisera kit
(Denka Seiken, Tokyo, Japan) designed to detect the heat-
stable antigen was utilized by the passive hemagglutina-
tion method (PHA). For preparation of the sensitized bac-
terial antigen solution, the bacteria and 0.25 ml of each
extraction solution provided in the kit were mixed. To pre-
pare sensitized red blood cells for use in the PHA test, 0.5
ml of each bacterial antigen was incubated with fixed
chick red blood cells at 37°C for 30 min. The PHA test was
conducted by placing one drop of each antiserum and 25
μl of sensitized red blood cells into microplate wells and
incubating for 30 min. Examination for agglutination in
each well was utilized to determine the serotypes of the C.
jejuni isolates.
Ethical review
The sentinel surveillance for diarrhea syndrome is one of
the national disease surveillance systems established by
Taiwan CDC. Sentinel physicians in individual hospitals,
clinics and medical centers reported outpatients suspected
of catching diarrhea and sent specimens for enteric bacte-
rial pathogens identification. The present study was car-
ried out through sentinel surveillance and reviewed by
Taiwan CDC, which does not require oversight by an eth-
ics committee.
Results
Campylobacter isolates from clinical fecal specimens
To study the prevalence rate of Campylobacter in children
in northern Taiwan, a total of 894 fecal specimens from
different diarrheal patients were tested for Campylobacter.
Sixty-one isolates (61/894, 6.8%) including 58 C. jejuni
(58/61, 95.1%) and 3 C. coli (3/61, 4.9%) isolates were
identified by direct plating, followed by biochemical reac-
tions and PCR. Two selective culture media (mCCDA and
CSM) were used and the recovery rates from both were the
same (data not shown). During the 15 months of the
study, the highest and lowest positive rates were observed
in February 2005 (4/22, 18.2%) and August 2004 (1/82,
1.2%), respectively. Most isolates were recovered in winter
(December to February, 25/225, 11.1%), followed by
spring (March to May, 15/214, 7.0%), autumn (Septem-
ber to November, 11/225, 4.9%), and summer (June to
August, 10/230, 4.3%). The positive rate of Campylobacter
and its relationship with the average temperature during
each month are shown in Table 1 and Figure 1, respec-
tively.
Basic information about infected patients
Of the 61 Campylobacter  isolates, 29 (47.5%) and 32
(52.5%) each were gathered from male and female chil-
dren, respectively (Figure 2). The age of these 61 patients
ranged from 10 months to 17 years old (Figure 2). We fur-
ther divided them into 5 age-groups according to the
school age (see Methods). Children in the < 4 group had
the highest positive rate (28/61, 45.9%), followed by the
4–7 group (16/61, 26.2%), group 7–10 (9/61, 14.8%),
group > 13 (7/61, 11.5%) and group 10–13 (1/61, 1.6%).
Bloody diarrhea is a classical symptom in children with
campylobacteriosis [21]. Of the infected children, 25 out
of 61 (41%) had bloody diarrhea (Table 2). Most of these
25 children belonged to the < 4 age group (14/25, 56%),BMC Infectious Diseases 2008, 8:151 http://www.biomedcentral.com/1471-2334/8/151
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followed by group 4–7 (4/25, 16%), group 7–10 (3/25,
12%), group > 13 (3/25, 12%) and group 10–13 (1/25,
4%). Thirty-nine out of 61 (39/61, 63.9%) presented with
fever, and most of these 39 children belonged to the < 4
age group (14/39, 35.9%), followed by group 4–7 (9/39,
23.1%), group 7–10 (9/39, 23.1%), group > 13 (6/39,
15.4%), and group 10–13 (1/39, 2.5%).
Antimicrobial susceptibility
The Clinical and Laboratory Standards Institute (CLSI)
has approved the agar dilution method as a standard sus-
ceptibility testing method for Campylobater. Due to the
time-consuming procedures, it is rarely carried out in rou-
tine diagnostic laboratories. The easier and less expensive
disc diffusion method represents a good correlation while
comparing with agar-based dilution method and provides
an alternative choice for antibiotic susceptibility test of
Campylobacter  [20,22]. Since the disc diffusion method
was found to be a reliable and easy tool for monitoring
the prevalence of Campylobacter strains, we applied this
method for antimicrobial susceptibility test in this study.
The results of the susceptibility testing for 61 Campylo-
bacter isolates are shown in Table 3. All C. jejuni and C. coli
isolates in this study were resistant to cephalothin
(100%), and most showed resistance to the four other
drugs tested, including tetracycline (93.4%), nalidixic acid
(91.8%), ciprofloxacin (90.2%), and ampicillin (85.5%).
Five out of the ten antimicrobial agents tested, including
streptomycin, chloramphenicol, gentamicin, clindamy-
cin, and erythromycin, tended to result in a lower resist-
ance rate as listed in Table 3. Cross-resistance between
nalidixic acid and ciprofloxacin was found in all qui-
nolone-resistant isolates.
Table 1: Positive rate of campylobacteriosis for each month from December 2003 to February 2005
Year 03 04 05
M o n t h 1 2 1 23 4 56789 1 0 1 11 2 1 2
N o .  o f  s p e c i m e n s 2 6 4 5 3 29 1 4 9 7 46 97 98 29 97 05 6 6 0 4 0 2 2
N o .  o f  p o s i t i v e s 4 5 14 6 5451254 7 4 4
Positive rate (%) 15.4 11.1 3.1 4.4 12.2 6.8 5.8 6.3 1.2 2.0 7.1 7.1 11.7 10.0 18.2
Relationship between the Campylobacter isolation rate and the average temperature of each season Figure 1
Relationship between the Campylobacter isolation rate and the average temperature of each season.BMC Infectious Diseases 2008, 8:151 http://www.biomedcentral.com/1471-2334/8/151
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Serotyping of the 58 C. jejuni isolates
For serotyping, 24 out of the 58 C. jejuni isolates (24/58,
41.4%) were typable and belonged to 9 different sero-
types according to Penner's scheme (Table 4). Five of the
above 9 serotypes contained only one isolate and the
other four types contained two to eight isolates. The most
prevalent serotypes among these isolates were Penner's
type 2 (group B), followed by type 6,7 (group F) and type
11 (group J). Thirty-four (58.6%, 34/58) strains were
defined as "untypable", including 14 (41.2%, 14/34)
strains that failed to agglutinate in the presence of any of
the antisera used in the present study and 20 that reacted
with two or more types of antisera. Serotyping using Pen-
ner's scheme was sufficient for identification of about half
of the human clinical strains.
Discussion
Over the past years, the limited number of reports regard-
ing  Campylobacter  infection may lead to the possible
under-estimation of the incidence of campylobacteriosis
in Taiwan. Due to heightened public concern, we have
already set up a Campylobacter reference laboratory at the
Taiwan CDC to be responsible for the surveillance study
since 2003. In this study, we provided an epidemiological
Table 2: Symptoms of the 61 patients in the five age groups
Age group (year) No. of patients No. (%) of Bloody diarrhea No. (%) of fever No. (%) of times of diarrhea/day
1~4 > 4
< 4 28 14 (50) 14 (50) 22 (78.6) 7 (25)
4–7 16 4 (25) 9 (56.3) 8 (50) 2 (12.5)
7–10 9 3 (33.3) 9 (100) 8 (88.9) 5 (55.6)
10–13 1 1 (100) 1 (100) 1 (100) 0
> 13 7 3 (42.9) 6 (85.8) 6 (85.7) 2 (28.6)
Total 61 25 (41) 39 (63.9) 45 (73.8) 16 (26.2)
Distribution of Campylobacter isolates according to age and sex of the 61 patients Figure 2
Distribution of Campylobacter isolates according to age and sex of the 61 patients.BMC Infectious Diseases 2008, 8:151 http://www.biomedcentral.com/1471-2334/8/151
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analysis of Campylobacter infection, including the isola-
tion rate, age, seasonal distribution, antimicrobial drug
susceptibility patterns, and serotypes of the isolates from
pediatric patients in northern Taiwan from 2003 to 2005.
Among the 894 clinical specimens obtained from chil-
dren tested for campylobacteriosis, 61 isolates (6.8%)
were recovered in our study. This percentage was compa-
rable to that obtained by van Hees et al. at 6.3% [23]. In
addition,  Campylobacter  may present much more fre-
quently in northern Taiwan (6.3%) while compare to the
report of campylobacteriosis in central Taiwan by Lin et
al. (2.5%) [16]. The age distribution within the 61
patients peaked in the < 4 group (41%, Figure 2) and this
was also observed by Feizabadi et al. in Iran and Lin et al.
in central Taiwan [16,24]. Therefore, the preschool chil-
dren may have a relatively high risk of being infected by
this important pathogen.
There are many species among Campylobacter  cause
human diarrhea, such as C. jejuni, C. coli, C. fetus, C. lari,
and C. upsaliensis. Campylobacter jejuni and C. coli are the
only species (95.1% and 4.9%, respectively) isolated from
specimens examined in our study. This suggests that
Campylobacter infection of children in northern Taiwan is
similar to other countries [25,26]. Feizabadi et al. and
Gallay et al. have both reported the rates of C. jejuni and
C. coli in human specimens in Iran and France [5,24],
respectively. The percentage of C. jejuni in their isolated
strains was 85.8% and 76.2% and that of C. coli was
14.2% and 17.2%, respectively. In these two studies, C.
coli seemed to be present at a higher percentage compared
to our study. To obtain the true rates of C. jejuni and C.
coli, both groups concluded that PCR method is needed
on the classification of the hippurate hydrolysis negative
strains at the genetic level [17,18]. In our study, all three
hippuricase negative isolates were confirmed as C. coli by
PCR. Our data reflect the reliable rates of C. jejuni and C.
coli in northern Taiwan.
According to the results of the seasonal analysis in our
study (Figure 1), Campylobacter occupied a relative higher
percentage in the winter of 2003 (10/103, 9.7%) and
2004 (15/122, 12.3%) (winter vs. summer, 95% CI =
0.0190~0.1162), differing from that observed among
warmer months such as summer in other reports (10/230,
4.3%) [27]. This seasonal trend was also observed by Lin
et al. in central Taiwan and by van Hees et al., who
reported the percentage of Campylobacter  enteritis as
35.2% in winter, 24.1% in summer, and 8.2% in winter,
4.3% in summer, respectively [16,23],. The mechanism
which influenced on the different seasonal trend of
campylobacteriosis in Taiwan needs to be further studied.
Concern regarding the antimicrobial resistance of human
Campylobacter isolates has increased in the clinical treat-
ment of patients with campylobacteriosis. Our results
revealed that a higher proportion of isolates are resistant
to tetracycline, nalidixic acid, ciprofloxacin (Table 3) in
comparison with that in NARMS 2004 by the US CDC
(93.4%, 91.8% and 90.2% vs 46.1%, 19.6%, and 19.0%,
respectively) [28]. Another study was performed by Li et
al. in southern Taiwan [29]. The three highest rates of
resistance were also observed to be against tetracycline
(92.4%), nalidixic acid (80.6%), and ciprofloxacin
(57%), and the three lowest rates of resistance were
against gentamicin (10.8%), erythromycin, (18.3%) and
clindamycin (18.3%). Gallay et al. also reported the resist-
ance rates of human Campylobacter isolates in France to
tetracycline, ciprofloxacin, and ampicillin as 32.9%,
28.1%, and 34.2%, respectively. The rates of the above
three drugs seem to be significantly lower than that of
those in northern Taiwan. Erythromycin has been the rec-
ommendation of choice for treatment of campylobacteri-
osis in clinical therapy [30]. To date, the resistance rate
reported for erythromycin has varied widely [5]. In the
present study, there were only 2 (3.3%) isolates that dem-
Table 3: Antimicrobial drug resistance of the 61 Campylobacter 
isolates
Antibiotic drug (μg) Number of resistant (%)
Campylobacter n = 61
Ampicillin (10) 52 (85.2)
Cephalothin (30) 61 (100)
Chloramphenicol (30) 10 (16.4)
Ciprofloxacin (5) 55 (90.2)
Clindamycin (2) 3 (4.9)
Erythromycin (15) 2 (3.3)
Gentamicin (10) 6 (9.8)
Nalidixic Acid (30) 56 (91.8)
Tetracycline (30) 57 (93.4)
Streptomycin (10) 15 (24.6)
Table 4: Penner's serotypes of the 58 C. jejuni isolates
Penner's serotype No. of isolates (%)
Penner's type 2 8 (13.9)
Penner's type 3 2 (3.5)
Penner's type 4 1 (1.7)
Penner's type 5 1 (1.7)
Penner's type 6 5 (8.6)
Penner's type 7 1 (1.7)
Penner's type 10 1 (1.7)
Penner's type 11 4 (6.9)
Penner's type 14 1 (1.7)
Untypable 34 (58.6)
Total 58 (100)BMC Infectious Diseases 2008, 8:151 http://www.biomedcentral.com/1471-2334/8/151
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onstrated a resistant pattern. According to our results for
the susceptibility test, erythromycin and clindamycin may
be the best choices to treat patients with campylobacteri-
osis in northern Taiwan.
As we know, Campylobacter could cause not only enteritis
but also other disease like GBS. Campylobacter isolates in
different serotypes may be the agents of the different
symptoms (eg. Penner's HS:19 for GBS). Serotyping,
therefore, has the benefit for the epidemiologic investiga-
tion of Campylobacter. The distribution of C. jejuni sero-
types in northern Taiwan was evaluated in the present
study (Table 4) since no other reports were available for
the past years. Our results revealed that Campylobacter iso-
lates in northern Taiwan were clustered into 9 Penner's
serotypes and 58.6% remained untypable. This observa-
tion may be explained the presence of different Camylo-
bacter serotypes in Taiwan from those in Japan. In the
future, homemade antisera that recognize the serotypes of
Campylobacter present in Taiwan may be required to gain
more complete information about the character of these
isolates.
Conclusion
The Taiwan CDC provided a complete epidemiological
analysis of Campylobacter infection, including the isola-
tion rate, age, seasonal distribution, antimicrobial drug
susceptibility patterns, and serotypes of the isolates from
pediatric patients in northern Taiwan from 2003 to 2005.
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